破解医药研发九死一生困局！省人大代表李小军：建立容错机制

Core Viewpoint - The Guangdong Provincial People's Congress is focusing on "unbinding" the biopharmaceutical industry to effectively stimulate new productive forces in the sector [2] Group 1: Innovation Assessment Mechanism - The company suggests utilizing big data and AI technologies to explore a market-matching valuation mechanism for assessing innovative pharmaceutical research and development projects [2][4] - A comprehensive evaluation guideline for different stages of biopharmaceutical research projects is recommended, along with a dynamic adjustment mechanism for asset valuation based on emerging technologies and market changes [4] Group 2: Talent Recruitment Mechanism - The company proposes establishing offshore talent recruitment stations in global pharmaceutical hubs to attract top-tier talent, including Nobel laureates and leading scientists [5] - A market-oriented evaluation approach is suggested to give companies greater autonomy in talent assessment, linking individual growth with the long-term development of Guangdong's biopharmaceutical industry [5] Group 3: Error Tolerance Mechanism - The establishment of a systematic error tolerance mechanism at the provincial level is recommended to encourage innovation in the biopharmaceutical sector, which is characterized by high investment, long cycles, and high risks [8][9] - Specific measures include defining tolerable and intolerable errors, setting loss tolerance gradients based on company development stages, and enhancing assessment weights for research investment during strategic transitions [8][9] Group 4: Financial Support for Innovation - The company suggests setting up a provincial innovation risk compensation fund to provide subsidies for failed R&D projects and support banks in offering credit to companies with error tolerance records [9] - A commitment of 10-15 billion yuan for R&D during the 14th Five-Year Plan period has been announced, with over 200 ongoing projects in various therapeutic areas [9]